1991
DOI: 10.3109/10408369109106863
|View full text |Cite
|
Sign up to set email alerts
|

Hypophosphatasia and the Extracellular Metabolism of Inorganic Pyrophosphate: Clinical and Laboratory Aspects

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

1
50
0
14

Year Published

1995
1995
2020
2020

Publication Types

Select...
8

Relationship

0
8

Authors

Journals

citations
Cited by 35 publications
(65 citation statements)
references
References 249 publications
(24 reference statements)
1
50
0
14
Order By: Relevance
“…Subject (26). Failure of TNSALP to hydrolyze PPi, an inhibitor of biomineralization, offers a plausible explanation for the associated skeletal disease (8,10). Hypophosphatasia, however, raises intriguing questions about the physiological role of TNSALP elsewhere in the body, because organs other than the skeleton that are also TNSALP-rich (e.g., liver, kidney, adrenal glands) do not significantly malfunction (2,8).…”
Section: Resultsmentioning
confidence: 99%
See 1 more Smart Citation
“…Subject (26). Failure of TNSALP to hydrolyze PPi, an inhibitor of biomineralization, offers a plausible explanation for the associated skeletal disease (8,10). Hypophosphatasia, however, raises intriguing questions about the physiological role of TNSALP elsewhere in the body, because organs other than the skeleton that are also TNSALP-rich (e.g., liver, kidney, adrenal glands) do not significantly malfunction (2,8).…”
Section: Resultsmentioning
confidence: 99%
“…In hypophosphatasia, three phosphocompounds (phosphoethanolamine [PEA], inorganic pyrophosphate [PPi], and pyridoxal 5'-phosphate [PLP]) accumulate endogenously and appear, therefore, to be natural substrates for TNSALP (8,9). PPi is an inhibitor of calcification and, accordingly, increased levels could account for the skeletal disease (8,10). Identification of 12 missense mutations to date within the TNSALP gene (11)(12)(13) and Henthom, P. S., M. Raducha, V. Fimiani, K. N. Fedde, and M. P. Whyte, manuscript in preparation) associated with hypophosphatasia and a transfection study, which showed that-one of these nucleotide changes destroyed the enzyme's catalytic action ( 11) (8).…”
mentioning
confidence: 99%
“…There are at least four ALP isoenzymes, encoded by four separate genes: three tissue-specific ALPs (Bintestinal,^Bplacental,^and Bgerm cell^) and the ubiquitous TNSALP, especially abundant in the liver, bone, and kidney [2,6,8,9], but also expressed in the brain, particularly in the cortical sensory areas [10]. TNSALP accounts for approximately 95 % of the total serum ALP activity, and PPi and PLP are currently considered its main physiological substrates.…”
Section: Alkaline Phosphatasementioning
confidence: 99%
“…The main clinical signs are related to defective bone and teeth mineralization (rickets, osteomalacia, fractures, teeth loss), but other systemic manifestations can be present in the severe forms (seizures, respiratory and kidney problems, chronic pain, weakness, etc.). The main diagnostic laboratory abnormalities are low serum ALP and TNSALP activity (hypophosphatasemia) and increased levels of ALP substrates (inorganic pyrophosphate (PPi), pyridoxal-5'-phosphate (PLP, the active metabolite of vitamin B6), and phosphoethanolamine (PEA)) [2][3][4][5][6][7].…”
Section: Introductionmentioning
confidence: 99%
“…Decreased production of ALP leads to the endogenous accumulation and toxicity of PPi. The PPi accumulation causes defective skeletal mineralization manifesting as osteomalacia and development of articular chondrocalcinosis in affected adults [2,3].…”
Section: Introductionmentioning
confidence: 99%